“…Nevertheless, their relatively high cytotoxicity, difficulties in production and purification, low proteolytic stability, and susceptibility to salt in physiological environments hinder their clinical utility . Hence, various strategies have been utilized to adapt AMPs, such as entrapping AMPs into carriers synthesized with polymers, liposomes, or lipids, − modifying their sequences by repeating, substituting or functionalizing, − and altering of the molecule structure by branching, linearization or cyclization . Additionally, strategies like conjugating AMPs with other functional molecules, such as siderophores and polylactic acid nanoparticles, are also feasible. , However, the high investment, limited outcome, and lengthy cost-recovery period associated with developing entirely new antimicrobial agents have discouraged pharmaceutical companies .…”